Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability

Overview of attention for article published in Journal of Neurology, July 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,003 followers.

RT @NNTonthefly: New NNT→Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. https://t.co/E1p54edhQR

New NNT→Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. https://t.co/E1p54edhQR

Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. #MS J Neurology http://t.co/xcMTD57BU8